Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

99
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
99
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

66
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
66
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

117
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
117
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

645
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

151
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
151
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

69
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise Capacity, Endothelial Function, Muscle Mass, and Strength in Pediatric Patients With Fontan Circulation.

CJC pediatric and congenital heart disease·2026
Same author

The impact of climate change on psychiatric decompensation: A case report using the climate biopsychosocial framework.

The journal of climate change and health·2026
Same author

Beta-Adrenergic Stimulation and <i>MYH7</i> G256E Mutant Gene Dosage Drive Hypertrophic Cardiomyopathy Phenotype Penetrance.

bioRxiv : the preprint server for biology·2026
Same author

Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement.

American journal of respiratory and critical care medicine·2026
Same author

Advanced Molecular, Metabolic, and Imaging Approaches to Characterizing Right Ventricular Failure: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Python metabolomics uncovers a conserved postprandial metabolite and gut-brain feeding pathway.

Nature metabolism·2026

Related Experiment Video

Updated: Nov 7, 2025

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.8K

Improving Right Ventricular Function by Increasing BMP Signaling with FK506.

Mario Boehm1,2,3, Xuefei Tian1,2, Md Khadem Ali1,2

  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine.

American Journal of Respiratory Cell and Molecular Biology
|May 3, 2021
PubMed
Summary

FK506 enhances bone morphogenetic protein (BMP) signaling, directly improving right ventricular (RV) function and reducing fibrosis in pulmonary arterial hypertension (PAH) models, independent of its effects on pulmonary vasculature.

Keywords:
BMPR2FK506cardiac fibrosispulmonary hypertensionright ventricle

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.3K
Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
04:49

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension

Published on: June 14, 2024

951

Related Experiment Videos

Last Updated: Nov 7, 2025

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.8K
Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.3K
Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
04:49

Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension

Published on: June 14, 2024

951

Area of Science:

  • Cardiovascular Research
  • Pulmonary Hypertension
  • Molecular Cardiology

Background:

  • Right ventricular (RV) function is critical for survival in pulmonary arterial hypertension (PAH).
  • Previous studies suggested FK506 (tacrolimus) improves RV function by reducing pulmonary vascular remodeling.
  • Direct cardiac effects of FK506 on the pressure-overloaded RV remain unclear.

Purpose of the Study:

  • To investigate the direct effects of FK506 on RV structure and function in a model of fixed RV afterload.
  • To determine if FK506 improves RV fibrosis and microvasculature independent of its immunosuppressive properties.

Main Methods:

  • Pulmonary artery banding (PAB) in wild-type and Bmpr2 mutant mice to induce RV pressure overload.
  • Longitudinal assessment of RV function and strain using cardiac magnetic resonance imaging during FK506 infusion.
  • Analysis of RV fibrosis, capillarization, and molecular mechanisms in cardiac cells.

Main Results:

  • FK506 therapy restored cardiac BMP signaling, significantly reducing RV fibrosis in a BMP-dependent manner.
  • FK506 preserved RV capillarization and improved RV function and strain over time.
  • Mechanistically, FK506 required ALK1 and BMPR2 in cardiac fibroblasts to inhibit TGFβ1-induced proliferation and collagen production.

Conclusions:

  • Increasing cardiac BMP signaling with FK506 directly improves RV structure and function in pressure-overloaded conditions.
  • These beneficial effects are independent of FK506's impact on pulmonary vascular remodeling.
  • FK506 represents a potential therapeutic strategy targeting direct RV improvement in PAH.